SCHEMBL2679844

SCHEMBL2679844

Cc1ccc(C(=O)Nc2ccc(Cl)c(Cl)c2)cc1NC(=O)C=Cc1cncnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
LCK P06239 1/20 0.48
KIT P10721 1/20 0.48
SRC P12931 1/20 0.48
MAPK14 Q16539 1/20 0.48
TP53 P04637 4/20 0.47
BRAF P15056 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
ACHE P22303 1/20 0.44
CSF1R P07333 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078767 1.00 MAPT (0.49) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2679308 0.95 MAPT (0.49) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2678790 0.91 LCK (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL10077760 0.91 LCK (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL10054898 0.91 NPC1 (0.51) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2679216 0.89 NAMPT (0.57) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL10078412 0.89 NAMPT (0.57) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2679066 0.89 BRAF (0.55) LCKKITSRCMAPK14BRAF
SCHEMBL10078411 0.89 BRAF (0.55) LCKKITSRCMAPK14BRAF
SCHEMBL10077696 0.88 LMNA (0.49) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR MAPT 1476/4885NPC1 4708/4885RAB9A 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.